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Post-translational histone H3 modifications regulate
transcriptional competence. The mechanisms by
which the epigenome is regulated in response to
oncogenic signaling remain unclear. Here we show
that H3K4me3 is increased in breast tumors driven
by an activated PIK3CA allele and that inhibition of
PI3K/AKT signaling reduces promoter-associated
H3K4me3 in human breast cancer cells. We show
that the H3K4 demethylase KDM5A is an AKT target
and that phosphorylation of KDM5A regulates its
nuclear localization and promoter occupancy. Sup-
porting a role for KDM5A in mediating PI3K/AKT
transcriptional effects, the decreased expression in
response to AKT inhibition of a subset of cell-cycle
genes associatedwith poor clinical outcome is blunt-
ed by KDM5A silencing. Our data identify a mecha-
nism by which PI3K/AKT signaling modulates the
cancer epigenome through controlling H3K4 methyl-
ation and suggest that KDM5A subcellular localiza-
tion and genome occupancy may be pharmacody-
namic markers of the activity of PI3K/AKT inhibitors
currently in clinical development.
INTRODUCTION
The PI3K/AKT signaling pathway is frequently activated in hu-
man cancers. PI3K phosphorylation of PIP2 to PIP3 promotes
the phosphorylation and activation of AKT (Engelman et al.,
2006; Thorpe et al., 2015). AKT-mediated substrate phosphory-
lation regulates the transcription and translation of genes
required for cellular growth, metabolism, and survival; critical
events in transformation and oncogenesis (Manning and Cant-
ley, 2007). Constitutive activation of the PI3K/AKT pathway oc-
curs in more than 50% of human breast cancers, most
commonly through mutational activation of the PIK3CA gene,
mutational activation or amplification of AKT1, AKT2, or AKT3,
or functional loss of the lipid phosphatase PTEN, whose function
counteracts that of PI3K (Cancer Genome Atlas Network, 2012).2692 Cell Reports 15, 2692–2704, June 21, 2016 ª 2016 The Authors
This is an open access article under the CC BY-NC-ND license (http://The frequency of PI3K pathway alterations in human cancers has
prompted the development of PI3K-pathway-specific inhibitors,
with recent focus on pan-PI3K, isoform-selective PI3K, and AKT
inhibitors (Cancer Genome Atlas Network, 2012). Current and
recent clinical trials evaluating PI3K-inhibitor monotherapy in
solid tumors demonstrate limited efficacy and durability as
response rates are relatively low, and tumors frequently recur
(Juric et al., 2015; Rodon et al., 2013). A better understanding
of the mechanisms by which activated PI3K promotes cancer
and informative pharmacodynamic markers of PI3K/AKT inhibi-
tor activity is needed to rationally design effective combination
therapeutics involving PI3K inhibitors.
The role of chromatin modification and the induction of a tran-
scriptionally competent state in PI3K-mediated oncogenesis are
not well understood. AKT phosphorylates EZH2, an H3K27 his-
tonemethyltransferase, inhibiting EZH2methyltransferase activ-
ity and reducing H3K27 trimethylation (H3K27me3) (Cha et al.,
2005). AKT-mediated EZH2 phosphorylation also enhances
EZH2 function as an oncogenic transcriptional co-activator by
associating with androgen receptor and other transcription fac-
tors (Xu et al., 2012). Phosphorylation of the polycomb repres-
sive complex 1 (PRC1) component BMI1 by AKT enables PI3K/
AKT-mediated epigenetic repression of the CDKN2A locus (Liu
et al., 2012). AKT activation counteracts induction of p53-depen-
dent senescence through the phosphorylation of the histone
acetyltransferase MOZ (Rokudai et al., 2013). It is currently un-
known whether PI3K/AKT regulates the function of additional
chromatin modifiers and, if so, whether this regulation is impor-
tant for oncogenic growth.
Changes to the chromatin landscape are associated with can-
cer development (Kandoth et al., 2013). Clinical data indicate
that H3K4me3may be elevated in breast, kidney, and colon can-
cers and correlates with a poor clinical outcome (Benard et al.,
2014; Liu et al., 2012; Mungamuri et al., 2013). The H3K4 histone
demethylase KDM5A/JARID1A/RBP2 functions as a transcrip-
tional repressor by removing di- and tri-methyl groups (Christen-
sen et al., 2007; Klose et al., 2007). Originally characterized
as binding to the retinoblastoma protein (RB1), KDM5A regu-
lates RB1-dependent differentiation and senescence (Benevo-
lenskaya et al., 2005; Lopez-Bigas et al., 2008). Overlapping
KDM5A and E2F binding sites suggests some RB1-dependent
cell-cycle regulation occurs via KDM5A (Lopez-Bigas et al.,.
creativecommons.org/licenses/by-nc-nd/4.0/).
2008). KDM5A association with the Notch/RBP-J repressor
complex, Myc, Mad1, and HDACs, suggests KDM5A may have
diverse oncogenic functions (Ge et al., 2010; Liefke et al.,
2010; Secombe et al., 2007). Loss of KDM5A expression has
been shown to reduce cell proliferation, apoptosis, and tumori-
genesis in cell culture and in vivo models (Cao et al., 2014b;
Hou et al., 2012), but these activities are independent of
KDM5A catalytic function. KDM5A was reported to mediate a
drug resistant state in breast and lung cancer cells characterized
by EGFR mutation when treated with tyrosine kinase inhibitors
(Hou et al., 2012; Sharma et al., 2010).
Here, we demonstrate that PI3K/AKT modulates H3K4me3
and identify a mechanism by which PI3K/AKT regulates
KDM5A. We show that KDM5A subcellular localization and
genome occupancy is dependent on PI3K/AKT in breast cancer
cell lines andmurine tumormodels.Moreover, PI3K/AKT-depen-
dent transcriptional regulation of a set of genes associated with
cell-cycle regulation requires KDM5A. Finally, we show that AKT/
KDM5A-regulated gene expression is associated with breast
cancer progression and is a predictor of poor clinical outcome.
RESULTS
PI3K/AKT Activation Mediates H3K4 Methylation
Previous studies demonstrated that AKT-mediated EZH2 phos-
phorylation reduces H3K27me3 and enhances transcription
(Cha et al., 2005). High H3K4me3 and low H3K27 methylation
are indicative of a poor clinical outcome in some cancers (Be-
nard et al., 2014; Cao et al., 2014a; Liu et al., 2012; Mungamuri
et al., 2013; Wei et al., 2008). We first examined if AKT regulates
H3K4 methylation in breast tumors. Primary murine mammary
tumors driven by doxycycline (dox)-inducible expression of the
human PIK3CAH1047R (Liu et al., 2011) show an increase in
H3K4me3 abundance upon PI3K activation (Figure 1A). Loss
of PIK3CAH1047R expression upon dox withdrawal or treatment
with the pan-PI3K inhibitor GDC-0941 (GDC) is sufficient to
reduce H3K4me3 in these tumors (Figures 1A and 1B). We
next analyzed H3K4me1/2/3 in a human breast cancer cell line
expressing the PIK3CAH1047R gene, T47D, following treatment
with the AKT inhibitor MK2206 (MK) (Figure 1C), the pan-PI3K
inhibitors GDC or BKM120 (BKM), or the p110a and p110b
isoform-specific inhibitors BYL719 (BYL) and AZD6482 (AZD),
respectively (Figures 1D and 1E). PI3K or AKT inhibition was suf-
ficient to reduce H3K4me3 over a time course, with maximum
reduction of H3K4me3 detectable after 72 hr of AKT/PI3K
inhibition (Figures 1C–1E). Similar results were obtained in other
breast cancer lines, suggesting that the effect is independent of
the mechanism by which the PI3K pathway has been activated
including HER2 amplification/overexpression (BT474, MDA-
MB-361, Cal-148), PIK3CA mutation (T47D, MCF7, BT474,
MDA-MB-361), or PTEN loss (ZR751, BT549, MDA-MB-468,
HCC1937, HCC38, Cal-148) (Figures 1F and 1G). In addition,
the status of RB1 or TP53 did not impact the ability of AKT
inhibition to reduce H3K4me3. Moreover, H3K4me3 is reduced
by AKT inhibition in breast cell lines in which the AKT substrate
S6 remains phosphorylated (Figure 1F, HCC1937; HCC38;
BT549), suggesting the signal mediating the reduction in
H3K4me3 originates upstream of S6. Because both the PI3K/AKT and MEK/ERK pathways activate mTORC1, we inhibited
mTORC1 and MEK and found that neither was sufficient to
reduce H3K4me3 (Figures S1A and S1B), suggesting that
AKT alone regulates H3K4 methylation. Additional experiments
demonstrate that the ability of PI3K/AKT pathway inhibitors to
reduce the levels of H3K4 methylation is independent of their ef-
fects on apoptosis or senescence (Figures S1C–S1E). Despite
the known interactions between enzymes that regulate H3K4
methylation and RB1, stable RB1 knockdown does not alter
H3K4 methylation (Figure S1F).
AKT Inhibition Decreases Promoter-Associated
H3K4me3 and Cell-Cycle Gene Expression
H3K4me3 is abundant near transcriptional start sites (TSSs) and
is a mark of active transcription (Santos-Rosa et al., 2002). To
determine if AKT regulates promoter-localized H3K4me3, we in-
hibited AKT and performed H3K4me3 chromatin immunoprecip-
itation (ChIP), followed by next-generation sequencing (ChIP-
seq) over a time course. AKT inhibition reduces H3K4me3 in
comparison to vehicle-treated cells as early as 24 hr across all
TSSs (Figure 2A). Because PI3K/AKT inhibition also reduces
H3K4me2 (Figures 1C–1F), we performed H3K4me2 ChIP-seq
but did not detect any significantly regulated genomic loci
(data not shown). TSSs were ranked by the change in
H3K4me3 following either vehicle or 24 hr AKT inhibition (Fig-
ure 2B). AKT inhibition for 24 hr significantly reduces the
H3K4me3 near the TSS of 69 genes (R0.5 log fold decrease),
and this loss is maintained through 72 hr AKT inhibition (Figures
2C and S2A). We also inhibited AKT for 24 hr and used RNA
sequencing (RNA-seq) to define AKT-regulated transcripts.
Gene expression was not globally affected by 24 hr AKT inhibi-
tion (p = 0.20) (Figure 2D). Gene set enrichment analysis
(GSEA) of the RNA-seq dataset demonstrates AKT inhibition re-
duces transcription of cell-cycle, mitotic, and DNA replication-
associated genes (Figure 2E). AKT or PI3K inhibition is sufficient
to reduce the abundance of H3K4me3 at promoters of AKT-
regulated genes, which is detectable as early as 2 hr following
AKT inhibition and up to 24 hr (Figures 2F, 2G, and S2B). In
comparison, H3K4me3 of the a-tubulin promoter remains
unchanged. An AKT-mediated reduction in regulated gene
transcription is detected as early as 12 hr following AKT or
PI3K inhibition (Figures 2H, 2I, and S2C). AKT inhibition also
reduces the expression of these genes at the protein level (Fig-
ure 2J). Promoter-H3K4me3 and transcription of AKT-regulated
genes is also reduced with AKT inhibition in MCF7 (Figures S2D
and S2E) and ZR-75-1 (Figures S2F and S2G) breast cancer cell
lines.
Because PI3K/AKT inhibitors produce cytostatic effects (Junt-
tila et al., 2009), we testedwhether the reduction of the transcrip-
tion and protein expression of cell-cycle genes after AKT inhibi-
tion is a result of epigenomic changes rather than cell-cycle
arrest. We found that while PI3K/AKT inhibition decreases
H3K4me3, it moderately increases the number of cells in G1 (Fig-
ure S3A). We further arrested populations of T47D cells in G1, S,
or G2/M. While thymidine/nocodazole treatment with 15.5 hr
release enriches cells in G1 with a similar efficiency as AKT
inhibition (Figure S3B), it is not sufficient to reduce H3K4me3
(Figure S3C). H3K4me3 was similarly unchanged followingCell Reports 15, 2692–2704, June 21, 2016 2693
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Figure 1. PI3K/AKT Activity Regulates H3K4 Methylation in Breast Cancer
(A) Matched tumor biopsies derived from dox-treated iPIK3CAH1047R mice. A fraction of each tumor was isolated, followed by dox removal and a second biopsy.
Sections stained with the indicated antibodies. Randomly selected images shown. Scale bar, 100 mM. n = 3 mice/condition.
(B) Tumors derived from dox-treated iPIK3CAH1047R mice administered vehicle or GDC-0941 for 7 days prior to tumor isolation. Sections stained with the
indicated antibodies. Randomly selected images shown. Scale bar, 100 mM. n = 3 mice/condition.
(C) T47D breast cancer cells treated with MK2206 (1 mM) or DMSO for the indicated times and lysates acid extracted. Lysates were immunoblotted with the
indicated antibodies.
(D) T47D treated with GDC-0941 (1 mM) or DMSO for the indicated times and lysates acid extracted. Lysates were immunoblotted with the indicated antibodies.
(E) T47D treated with BKM120 (1 mM), BYL-719 (1 mM), AZD (1 mM) or DMSO for the indicated times and lysates acid extracted. Lysates were immunoblotted with
the indicated antibodies.
(F) A panel of breast cancer cell lines (blue, luminal; red, basal) was treated with MK2206 (1 mM) or DMSO for 72 hr and lysates acid extracted. Lysates were
immunoblotted for the indicated antibodies.
(G) Blot quantification of H3K4me3 abundance from (D). Results are representative of at least three independent experiments. Data are shown as mean ± SEM.
See also Figure S1.arrest in S or G2/M. These results are consistent with the hypoth-
esis that AKT signaling is driving changes to TSS-localized
H3K4me3 independently of cell-cycle arrest. We conclude that2694 Cell Reports 15, 2692–2704, June 21, 2016PI3K/AKT signaling is required for promoter H3K4me3, tran-
scriptional activation, and expression of cell-cycle-promoting
genes.
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Figure 2. AKT Regulates Promoter-Associated H3K4 Trimethylation and G1 and G2/M Gene Expression
(A) Wave plots of T47D cells treated with MK2206 (1 mM) for the indicated times, harvested and H3K4me3 ChIP-seq. DMSO, red; MK, black. 27,000 TSSs are
represented.
(B) Waterfall plot of rank ordered TSSs from (A).
(C) Wave plots of T47D cells treated with MK2206 (mM) for the indicated times, harvested, and H3K4me3 ChIP-seq. DMSO, red; MK, black. TSSs withR0.5 log
fold change (LFC) H3K4me3 are represented.
(legend continued on next page)
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KDM5A Is an AKT Substrate
KDM5 enzymes demethylate di- and tri-methylated H3K4 (Klose
et al., 2007). We utilized Scansite to examine whether KDM5
proteins are AKT substrates based on the AKT consensus motif
RxRxxS/T (Obenauer et al., 2003; Songyang et al., 1994).
Scansite analysis identified five AKT consensus motifs within
KDM5A (Figure 3A), all of which are highly conserved among
mammals and partially conserved in the divergent Xenopus
genus (Figure 3B). To investigate whether KDM5A is an AKT
target, we generated a compound KDM5A mutant that could
not be phosphorylated by AKT at any of the predicted sites
(KDM5AS225A, T285A, S287A, T1225A, S1255A; KDM5Amut5A). We
immunoprecipitated ectopically expressed wild-type KDM5A
or KDM5Amut5A and performed an in vitro kinase assay using re-
combinant AKT1 in the presence or absence of AKT inhibition.
Wild-type KDM5A is phosphorylated by AKT1 and this modifica-
tion is sensitive to AKT inhibition, whereas KDM5Amut5A is not
phosphorylated in the presence of AKT1 (Figure 3C). Wild-
type KDM5A is also phosphorylated in cell culture and its phos-
phorylation is sensitive to AKT inhibition (Figure 3D). In order to
investigate the impact of AKT signaling on KDM5A chromatin
association, we inhibited AKT and performed KDM5A ChIP-
seq. In the absence of AKT inhibition, 95% of KDM5A is TSS
localized (±5 kb) (Figure 3E). AKT inhibition for 24 hr increased
KDM5A recruitment to TSSs (Figure 3F), coincident with a
reduction in TSS H3K4me3 (Figures 2A and S4). These results
suggest that AKT-mediated KDM5A phosphorylation enhances
KDM5A promoter recruitment.
AKT Regulates KDM5A Subcellular Localization
FOXO phosphorylation by AKT leads to its cytoplasmic reten-
tion (Brunet et al., 1999). To investigate whether KDM5A phos-
phorylation by AKT changes KDM5A subcellular localization,
we ectopically expressed wild-type KDM5A and performed
KDM5A immunofluorescence in the presence and absence
of AKT inhibition. Under normal growth conditions, wild-type
KDM5A is both nuclear and cytoplasmic, and pharmacologic
AKT inhibition drives KDM5A into the nucleus (Figure 4A). AKT
inactivation via serum starvation increases nuclear KDM5A,
and growth factor stimulation relocalizes a substantial fraction
of wild-type KDM5A to the cytoplasm (Figure 4B). These effects
are similar to AKT-mediated FOXO phosphorylation. In contrast,
the subcellular localization of KDM5Amut5A that cannot be phos-
phorylated by AKT is not affected by the modulation of AKT ac-
tivity through serum starvation/stimulation or pharmacological
inhibition (Figure S5A). Biochemical fractionation in T47D cells(D) Transcript abundance (RNA-seq) in T47D cells treated with DMSO or MK220
(E) GSEA (GO biological processes) from T47D cells treated with MK2206 (1 mM
(F) T47D cells treated with MK2206 (1 mM) for the indicated times. Cells were harv
for the genes indicated. Data are shown as mean ± SEM; *p% 0.05, **p% 0.01
(G) T47D cells treated with GDC-0941 (1 mM), 24 hr. Cells were harvested; H3K4m
indicated. Data are shown as mean ± SEM; *p% 0.05, **p% 0.01, ***p% 0.001
(H) T47D cells treated withMK2206 (1 mM), 24 hr. RNAwas isolated prior to qPCRw
*p% 0.05, **p% 0.01, ***p% 0.001, Student’s t test.
(I) T47D cells treated with GDC-0941 (1 mM), 24 hr. RNA was isolated prior to qPC
SEM; *p% 0.05, **p% 0.01, ***p% 0.001, Student’s t test.
(J) T47D cells treated with MK2206 (1 mM) for the indicated times. Cell lysates w
See also Figures S2–S4.
2696 Cell Reports 15, 2692–2704, June 21, 2016that stably express wild-type HA-FLAG-KDM5A demonstrates
that nuclear localized and chromatin-bound KDM5A increases
with AKT inhibition (Figures 4C, S5B, and S5C). In contrast,
HA-FLAG-KDM5Amut5A cytoplasmic abundance is reduced,
instead shifting into the nuclear compartment in the absence
of AKT inhibition (Figures 4D and S5C). Tumors derived from
the dox-inducible PIK3CAH1047R murine tumor model further
demonstrate that PI3K pathway activation modulates KDM5A
subcellular localization. KDM5A strongly localizes to the
cytoplasm in PI3K-pathway activated tumors (Figure 4E). Dox
removal and thus loss of PIK3CAH1047R transgene expression
or treatment with the pan-PI3K inhibitor GDC-0941 is sufficient
to reduce cytoplasmic KDM5A localization and promote nuclear
KDM5A localization (Figures 4E and 4F).
To determine whether KDM5Amut5A insensitivity to AKT-medi-
ated phosphorylation and subsequent subcellular redistribution
increasesKDM5Amut5A recruitment to the promotersofAKT-regu-
lated genes, we performed HA-ChIP with T47D cells that stably
express wild-type HA-FLAG-KDM5A or HA-FLAG-KDM5Amut5A.
KDM5Amut5A promoter occupancy at AKT-regulated genes is
increased in comparison to wild-type KDM5A (Figure 4G).
Together, these results suggest KDM5A subcellular localization
is partially dependent on its phosphorylation by AKT, and
KDM5A phosphorylation by AKT decreases KDM5A recruitment
to the promoters of AKT-regulated genes.
AKT/KDM5A-Regulated Gene Expression Is Elevated in
Cancers and Is a Predictor of Poor Outcome
To examine the functional significance of KDM5A downstream of
PI3K/AKT signaling, we integrated the H3K4me3- and KDM5A-
ChIP-seqwith the RNA-seq data following AKT inhibition to iden-
tify genes regulated by AKT/KDM5A (Figure 5A). KDM5A recruit-
ment after 24 hr AKT inhibition is increased at all TSSs (69 total)
characterized by aR0.5 log fold reduction in H3K4me3 (Figures
2C and 5B). Promoter-localized H3K4me3, transcription, and
protein detection of AKT/KDM5A-regulated genes are reduced
following PI3K/AKT inhibition (Figures 2F–2J). To investigate
whether KDM5A is necessary for the transcription of AKT-regu-
lated genes, we utilized lentiviral shRNA expression vectors to
knock down KDM5A in the presence or absence of AKT inhibi-
tion and evaluated nascent RNA transcription. Nascent RNA
transcription of two direct AKT/KDM5A targets, AURKB and
E2F2, was no longer sensitive to AKT inhibition following
KDM5A knockdown (Figure 5C and S5C). Taken together, these
data suggest AKT regulates the expression of a set of cell-cycle
genes through KDM5A.6 (1 mM) for 24 hr. p = 0.20.
) for 24 hr and RNA-seq.
ested; H3K4me3 ChIP performed prior to qPCR at promoter-localized regions
, ***p% 0.001, Student’s t test.
e3 ChIP performed prior to qPCR at promoter-localized regions for the genes
, Student’s t test.
ithin the gene bodies for the genes indicated. Data are shown asmean ± SEM;
R within the gene bodies for the genes indicated. Data are shown as mean ±
ere immunoblotted with the indicated antibodies.
A B
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Figure 3. KDM5A Is an AKT Target
(A) Table indicating Scansite prediction of AKT consensus motifs within KDM5A in comparison to positive controls EZH2 and MOZ.
(B) Clustal W sequence alignment of orthologous KDM5A AKT consensus motifs.
(C) An IP/kinase assay was performed after transection of 293T cells with wild-type HA-FLAG-KDM5A or HA-FLAG-KDM5Amut5A. Flag-IP was used to isolate
KDM5A, followed by incubation with g-ATP, recombinant AKT1, and MK2206 (2 mM) where indicated. Transfer of radiolabeled phosphate to KDM5A was
detected by phosphorescence. Input cell lysates were immunoblotted with the indicated antibodies.
(D) A FLAG IP was performed after 293T transfection with wild-type HA-FLAG-KDM5A, followed by treatment with MK2206 (1 mM) for 1 hr. FLAG-IP was used to
isolate KDM5A followed by immunoblotting with the indicated antibodies. *KDM5A phosphorylated at S/T residues.
(E) Pie chart representing KDM5A genome localization from ChIP-seq data in T47D cells treated with DMSO for 24 hr.
(F) Wave plot of T47D cells treated with MK2206 (1 mM) for 24 hr, harvested, and KDM5A ChIP-seq. DMSO, red; MK, black.
See also Figure S4.To explore the functional relevance of AKT/KDM5A gene regu-
lation in cancer, the gene expression database Oncomine was
queried with the AKT/KDM5A regulated gene set (Rhodes
et al., 2004). Expression of these genes is significantly higher in
invasive breast carcinoma as compared to normal tissue (Fig-
ure 5D) and correlates with metrics of advanced stage disease
including increased metastatic event, increased breast cancer
recurrence, and increased death within 5 years of initial diag-
nosis (Figures 5E–5G). Thus, AKT-mediated modulation of pro-
moter H3K4 methylation may be an important component in
PI3K-activated oncogenesis.
DISCUSSION
The high frequency of PI3K/AKT pathway alterations in breast
and other cancers has led to the clinical development of PI3K
pathway inhibitors (Cancer Genome Atlas Network, 2012;
Thorpe et al., 2015). To date, the limited efficacy and durabilityof PI3K inhibitor monotherapy has encouraged the development
and testing of combination therapies targeting PI3K. Thus,
defining additional mechanisms by which PI3K/AKT contributes
to oncogenesis is essential to understanding the mechanics of
existing therapies and may support the development of potent
and durable PI3K/AKT combination therapies. Here, we demon-
strate that PI3K/AKT pathway activation promotes H3K4me3.
Further, we demonstrate that the H3K4 demethylase KDM5A is
an AKT target and that AKT may collaborate with KDM5A to
regulate the expression of a set of cell-cycle genes. This connec-
tion between PI3K/AKT signal transduction and the cancer epi-
genome suggests an additional mechanism by which PI3K/
AKT activation may contribute to oncogenesis. We demonstrate
that one action of PI3K/AKT inhibitors is to reduce the expression
of a subset of cell-cycle-promoting genes, including E2F tran-
scription factors and AURKB, and this requires KDM5A. This
mechanism is suggestive of nodes within the PI3K/AKT signaling
network that could be therapeutically exploited in PI3K-activatedCell Reports 15, 2692–2704, June 21, 2016 2697
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Figure 4. AKT Mediates KDM5A Subcellular Localization
(A) Immunofluorescence and immunoblot analysis were performed after transfection of Cos7 cells with wild-type HA-FLAG-KDM5A. Cells were treated with
MK2206 (1 mM) for 0.5 hr. Fixed cells were probed for FLAG (KDM5A), and lysates were probed with the indicated antibody, including HA (KDM5A). Scale bar,
35 mM.
(B) Immunofluorescence and immunoblot analysis were performed after transfection of Cos7 cells with wild-type HA-FLAG-KDM5A. Cells were starved for 24 hr
in 0% FBS DMEM and then growth factor stimulated with 10% FBS DMEM for 0.5 hr. Fixed cells were probed for FLAG (KDM5A), and lysates were probed with
the indicated antibody, including HA (KDM5A). Scale bar, 35 mM.
(C) T47D cells stably expressing wild-type HA-FLAG-KDM5A were treated with MK2206 (1 mM) for the indicated time and cells were biochemically fractionated.
KDM5A subcellular localization was quantified relative to control treatment. n = 3 independent experiments. Data are shown as mean ± SEM. *Student’s t test,
p% 0.05.
(legend continued on next page)
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breast tumors. Moreover, this mechanism suggests that
H3K4me3 and KDM5A subcellular localization could serve as
clinical pharmacodynamic markers for PI3K inhibition.
We present a model in which KDM5A phosphorylation by AKT
shifts KDM5A subcellular localization from the nuclear and chro-
matin-bound fractions to the cytoplasm, where it is unable to de-
methylate H3K4me2/3 (Figure 6). In contrast, non-phosphory-
lated KDM5A is predominantly nuclear and chromatin-bound.
While AKT PHdomains predominantly localize AKT to the cellular
membrane, phosphorylated AKT is present in the nucleus, where
the majority of KDM5A is accessible (Meier et al., 1997). Modu-
lation of KDM5A subcellular localization following PI3K/AKT acti-
vation or inhibition supports this model. Together, AKT/KDM5A
increase the expression of genes that facilitate cell-cycle pro-
gression, which may contribute in part to the increased cellular
proliferation frequently observed in PI3K-activated breast can-
cers. Increased nuclear/chromatin-associated KDM5A, either
through AKT inhibition or expression of non-phosphorylatable
KDM5Amut5A, enhances KDM5A promoter recruitment and
reduces AKT/KDM5A-regulated gene expression. However,
biochemical fractionation, immunofluorescence (IF), and immu-
nohistochemistry (IHC) from PI3K-activated mammary tumors
and cell lines demonstrate that some, but not all, KDM5A reloc-
alization is dependent on the modulation of PI3K/AKT activity.
While these data suggest that the relocalization of a fraction of
total KDM5A by AKTmight be sufficient to alter gene expression,
it is possible that AKT-mediated KDM5A phosphorylation regu-
lates other aspects of chromatin biology—e.g., the association
of KDM5A with other chromatin-bound complexes (HDACs,
KDM2B, RB1, IKKa/b).
We speculate that nuclear KDM5A may function as a tumor
suppressor by demethylating H3K4me3 and thus reducing the
transcriptional competence of a subset of cell-cycle-promoting
genes. Contrary to our findings, a previous study suggests
that breast cancer progression and lung metastasis requires
KDM5A expression, but utilization of the H483A demethylase
inactive mutant suggests that oncogenic KDM5A activity is inde-
pendent of its histone demethylase activity (Cao et al., 2014b).
Our model suggests AKT-driven KDM5A modulation and poten-
tial tumor suppressive function is dependent on KDM5A recruit-
ment to chromatin, and we speculate that KDM5A demethylase
activity may be important for this process. We propose that AKT
dictates KDM5A function at least in part by regulating its
subcellular compartmentalization, and the observed reduction
in TSS-associated H3K4me3 following AKT inhibition may be
dependent on intact KDM5A demethylase activity. It is likely(D) T47D cells stably expressing wild-type HA-FLAG-KDM5A and HA-FLAG-K
KDM5Amut5A subcellular localization was quantified relative to wild-type KDM5A
t test, p% 0.05.
(E) Matched tumor biopsies derived from dox-treated iPIK3CAH1047R mice. A fra
biopsy. Sections stained with the indicated antibodies. Quantification of cytopla
shown. Scale bar, 100 mM. n = 3 mice/condition. Data are shown as mean ± SEM
(F) Tumors derived from dox-treated iPIK3CAH1047R mice administered vehicle
indicated antibodies. Quantification of cytoplasmic and nuclear staining indicated
condition. Data are shown as mean ± SEM. ***p% 0.0001, Student’s t test.
(G) Stable T47D cells expressing wild-type HA-FLAG-KDM5A or HA-FLAG-KDM
localized regions for the genes indicated. Data are shown as mean ± SEM. *Stud
See also Figure S5.that KDM5A possesses separable nuclear and cytoplasmic
functions, as well as demethylase-dependent and demethy-
lase-independent functions. It is not uncommon that a tran-
scriptional regulator can serve both oncogenic and tumor sup-
pressive functions—e.g., Notch signaling functions as either
depending on tissue type (Kopan and Ilagan, 2009). Unconven-
tional functions of histone modifiers, either independent of cata-
lytic activity or dependent of catalytic activity but directed to
alternative, non-histone substrates, have recently been uncov-
ered, including non-histone EZH2 and HDAC substrates (Hama-
moto et al., 2015; Luo et al., 2000; Xu et al., 2012).
KDM5A and AKT have previously been implicated in cell-cycle
regulation via alternative mechanisms. KDM5A promoter occu-
pancy of the cyclin-dependent kinase inhibitors (CDKI) p21CIP1,
p27kip1, and p16ink4a suppresses CDKI expression, preventing
senescence in gastric and cervical cancer cell lines (Jiping
et al., 2013; Zeng et al., 2010). Our results are consistent with
these reports by suggesting that AKT promotes proliferative
competence via KDM5A phosphorylation and cytoplasmic re-
localization. In this model, we propose that AKT-meditated
KDM5A phosphorylation and the resulting increased tran-
scription of cell-cycle-promoting genes is an activating
event, whereas AKT inhibition is an inhibitory event that may
enable KDM5A chromatin recruitment, H3K4 demethylation,
and repression of cell-cycle-promoting gene expression. The
PI3K/AKT pathway is also an established regulator of the cell cy-
cle by modulating cyclin D translation through mTORC1 (Gera
et al., 2004). Moreover, CDK2/cyclin A-mediated AKT S477/
T479 phosphorylation and activation fluctuates over the cell
cycle, with maximal activity in G2 (Liu et al., 2014). Here,
enrichment of breast cancer cells in G2 (or G1 or M phase)
did not change H3K4me3, suggesting that AKT phosphoryla-
tion at S473 and T308 may be sufficient to modulate
KDM5A throughout the cell cycle independently of CDK2/
cyclin A. Thus, while it is established that AKT regulates the
cell cycle at multiple levels, our results show that this regulation
may be mediated in part through effects on the epigenome via
KDM5A.
The data presented here demonstrate that PI3K/AKT regulate
H3K4 methylation and that PI3K/AKT regulates the transcription
of cell-cycle-promoting genes via a KDM5A-dependent mecha-
nism. While KDM5A promoter occupancy is increased at pro-
moters that are also characterized by a reduction in H3K4me3
following AKT inhibition, KDM5A knockdown restores the
nascent transcription of only several AKT-regulated genes in
response to AKT inhibition (Figure 5C). Moreover, inducibleDM5Amut5A grown under normal conditions were biochemically fractionated.
. n = 3 independent experiments. Data are shown as mean ± SEM. *Student’s
ction of each tumor was isolated and followed by dox removal and a second
smic and nuclear staining indicated on the right. Randomly selected images
. **p% 0.01, ***p% 0.0001, Student’s t test.
or GDC-0941 for 7 days prior to tumor isolation. Sections stained with the
on the right. Randomly selected images shown. Scale bar, 100 mM. n = 3mice/
5Amut5A were harvested and HA-ChIP performed prior to qPCR at promoter-
ent’s t test, p% 0.05.
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Figure 5. AKT/KDM5A-Regulated Gene Expression Is Elevated in Breast Cancer and Is a Predictor of Poor Clinical Outcome
(A) Table integrating H3K4me3 ChIP-seq, KDM5A ChIP-seq, and RNA-seq data from T47D cells treated with MK2206 (1 mM) for 24 hr.
(B) KDM5A wave plot of T47D cells treated with MK2206 (1 mM) representing all TSSs (69 total) also characterized by aR0.5 LFC in H3K4me3.
(C) T47D cells treated with doxycycline (2 mg/ml) for 48 hr and then MK2206 (1 mM) for 12 hr where indicated. Nascent RNA was isolated prior to qPCR within the
AURKB and E2F2 gene bodies. Data are shown as mean ± SEM. *p% 0.05 and **p% 0.01, Student’s t test.
(D) Heat map representing Oncomine analysis of AKT/KDM5A regulated genes from Cancer Genome Atlas Network (2012) dataset.
(E) Correlation of mRNA expression of AKT/KDM5A-regulated genes and rate of patient metastatic event 5 years post-initial diagnosis. Analysis of three inde-
pendent studies from Oncomine.
(F) Correlation of mRNA expression of AKT/KDM5A regulated genes and rate of patient breast cancer recurrence 5 years after initial diagnosis. Analysis of three
independent studies from Oncomine.
(G) Correlation of mRNA expression of AKT/KDM5A regulated genes and rate of patient death 5 years after initial diagnosis. Analysis of three independent studies
from Oncomine.KDM5A knockdown fails to block AKT inhibition of H3K4me3 at
the promoters of many AKT-regulated genes (data not shown). It
is therefore possible that AKT regulates the function or activity
of the homologous KDM5 enzymes KDM5B or KDM5C. Some
genes identified here as AKT/5A-regulated genes are also
KDM5B targets in breast cancer (Yamamoto et al., 2014). While2700 Cell Reports 15, 2692–2704, June 21, 2016KDM5B does not share any of the AKT consensus motifs map-
ped in KDM5A, two of the five residues implicated in AKT-
mediated KDM5A phosphorylation are shared with KDM5C.
The possibility that AKTmodulates the function of histonemethyl
transferases in addition to KDM5A remains, which may also
explain how AKT inhibition reduces H3K4me3 at the promoters
Figure 6. AKT Regulates Cell-Cycle-Pro-
moting Genes through the Phosphorylation
and Subcellular Redistribution of KDM5A
Left: Active PI3K/AKT signaling phosphorylates
KDM5A and relocalizes KDM5A to the cytoplasm.
Abundance of promoter-associated KDM5A is
reduced, increasing TSS H3K4me3 and expres-
sion of AKT/5A-regulated genes.
Right: PI3K/AKT inhibition reduces AKT-mediated
KDM5A phosphorylation, increasing KDM5A nu-
clear localization and promoter occupancy. Here,
KDM5A demethylates H3K4me2/3 and reduces
expression of cell-cycle-promoting genes.of some AKT-regulated genes in the absence of KDM5A. Clearly,
more research is needed to evaluate the ability of PI3K/AKT
to cooperate with additional H3K4-directed demethylases and
methyltransferases to regulate H3K4me3 and transcriptional
competence.
Our findings suggest that H3K4 methylation is regulated by
PI3K/AKT. H3K4me3 affects transcriptional competence and
the expression of cell-cycle-promoting genes and is regulated
at least in part by AKT/KDM5A. This information could be ex-
ploited in the development and preclinical testing of combina-
tion therapies using compounds directed at PI3K/AKT with
novel compounds targeted to chromatin modifiers, such as
MLL1/MEN1, in the treatment of PI3K-activated tumors. Our
results suggest that reducing H3K4me3 through the chemical
inhibition of the histone methyltransferase MLL1 may have
therapeutic benefit in the treatment of PI3K-activated cancers.
Indeed, preclinical studies demonstrate that MLL1/MEN1
inhibition reduces tumor growth in models of breast cancer
with gain-of-function p53 mutations and in MLL-rearranged
leukemias (Borkin et al., 2015; Zhu et al., 2015). Clearly,
further studies are necessary to determine the therapeutic
benefit in targeting these two important nodes within the
PI3K pathway.
EXPERIMENTAL PROCEDURES
Cell Lines and Drugs
Cells were maintained at 37C and 5%CO2 in RPMI or DMEM + 10% FBS and
Pen-Strep. MK2206, GDC-0941, BKM120, BYL719, KIN193, RAD001, CHIR,
and MEK162 were purchased from Selleck.Cell RAnimal Models and In Vivo Treatment
Studies
Formalin-fixed tumors originating from the
previously characterized mammary specific,
doxycycline-inducible human PIK3CAH1047R ex-
pressing mice (MMTV-rtTA, TetO-PIK3CAH1047R;
iPIK3CAH1047R) were utilized for all experiments
described (Liu et al., 2011). Doxycycline (dox;
2 mg/ml) was administered in drinking water.
Where relevant, a fractionof the tumorwas isolated
followed with dox removal for 2 weeks prior to the
isolation and preparation of the remaining tumor.
Where applicable, GDC-0941 was reconstituted
in 0.5% (wt/vol) methylcellulose and 0.2% Tween
80 and administered by oral gavage (125 mg/kg,once daily) for 7 days prior to tumor isolation and preparation. Tumorswere iso-
lated and prepared within 3 hr of the final treatment. All mouse experiments
were conducted in accordance with protocols approved by the Institutional
Animal Care and Use Committees (IACUCs) of Dana Farber Cancer Institute
(DFCI) and Harvard Medical School (HMS).
Immunohistochemistry
Formalin-fixed, paraffin-embedded (FFPE) prepared tumors were sectioned
(HMS Rodent Histopathology Core) and mounted. Sections were deparaffi-
nized, hydrated, and antigens retrievedwith sodium citrate. Following blocking
of endogenous peroxidases, sections were blocked and incubated in primary
antibody overnight (4C). Primary antibodies used were as follows: AKTS473
(CST), H3K4me3 (Abcam), and KDM5A (Bethyl). Sections were washed and
incubated in secondary antibody, after which they were incubated with ABC
(Vector Labs), DAB developed (Vector Labs), and counter-stained with hema-
toxylin (Vector Labs). Sections were then dehydrated andmounted for imaging
(Nikon Eclipse E600). KDM5A subcellular localization was quantified with
blinded counting of cytoplasmic and nuclear KDM5A staining from more
than 190 cells across three randomized images obtained from three separate
mice per treatment group.
Cell Lysis and Immunoblotting
Cells were lysed in IP buffer (20 mM TrisHCl [pH 7.5], 150 mM NaCl, 5 mM
MgCl2, 1% NP-40) or fractionated (Pierce), supplemented with protease and
phosphatase inhibitors. Histones were acid extracted by lysing in Triton
extraction buffer (TEB; PBS, 0.5% Triton X-100) supplemented with protease
inhibitors. Lysates were centrifuged 6,500 3 g and histones were acid ex-
tracted from the resulting pellet with 1:1 TEB:0.8 M HCl. Histones were centri-
fuged and the supernatant precipitated with the addition of an equal volume of
50% TCA, then 12,000 3 g centrifugation. Histones were washed one time in
0.3 M HCl in acetone and two times in 100% acetone before vacuum drying
and resuspended in 20 mM Tris-HCl (pH 8.0). Whole cell lysate, fractionated
lysate, or acid-extracted proteins were separated using SDS-PAGE. Proteins
were transferred to nitrocellulose membranes and blocked in TBST+5% milk.eports 15, 2692–2704, June 21, 2016 2701
Proteins of interest were visualized and quantified after primary antibody
incubation (Odyssey, Li-Cor). Primary antibodies used were as follows: AKT,
AKTS473, AKTT308, S6, S6S240/44, BUB1B, AURKB, HA (CST), b-actin (Milli-
pore), KDM5A (Bethyl), H3, H3K4me3, H3K4me2, H3K4me, pS/T (Abcam),
E2F1, E2F2, PCNA (Santa Cruz), FlagM2, and a-tubulin (Sigma).
ChIP and ChIP-Seq
H3K4me3 ChIP was performed in T47D cells with 2.5 3 106 cells/IP, as previ-
ously described (Carroll et al., 2005). In brief, cells were treated as indicated.
Cells were crosslinked, lysed in SDS lysis buffer, and sonicated (Covaris).
H3K4me3 antibody (3 mg) was added to sonicated lysates per overnight (o/
n) IP. Protein A beads (Novex) were incubated with IP for 6 hr. Chromatin
was eluted and reverse crosslinked o/n and DNA was recovered with RNase
A incubation. Glycogen and proteinase K were added and incubated at
62C. DNAwas purified and eluted in Low TE. KDM5A andHAChIPs were per-
formed using the Sarkosyl method (Lee et al., 2006) with 2.5 3 108 cells/ChIP
and KDM5A #1416 antibody (10 mg) (Dr. William Kaelin) or HA ab9110 (5 mg)
(Abcam), respectively.
For samples that were Illumina sequenced, ChIP eluate was purified
(Ampure) and indices added (ThruPLEX-FD Prep kit, Rubicon Genomics).
Samples were then size selected (Pippin Prep, Sage Science) and purified
(Ampure). DNA quality and quantity was measured using a Fragment
Bioanalyzer and samples submitted to the Center for Functional Cancer Epige-
netics for sequencing on a Next-Seq Illumina platform.
RNA Isolation and qPCR
T47D cells were treated as described and RNA isolated (QIAGEN). Nascent
RNA isolation was performed according to manufacturer’s instructions (Life
Technologies). cDNA was synthesized using iScript (BioRad) and amplified
(ABI7300).
Bioinformatics
Human genome build 19 (hg19) was used as the reference genome. RNA-seq
data were aligned using Tophat and further analyzed using Cufflinks and
Limma for expression analysis (Ritchie et al., 2015; Trapnell et al., 2009,
2010). Gene set enrichment analysis was performed using the online tool
from the Broad Institute (Mootha et al., 2003). Boxplots were made in
Bioconductor/R. To determine significant differences in transcript expression,
a two-tailed unpaired or paired (whichever appropriate) Student’s t test was
used, and a two-sided p value of <0.05 was considered significant.
Sequencing data from ChIP experiments was aligned to hg19 using Bowtie
(Langmead et al., 2009). For peak calling, MACS2 was used (Feng et al.,
2012). For intersecting peak data, we used the Table Browser at the UCSC
genome bioinformatics web site (http://genome.ucsc.edu/). The mapBam.py
script to map reads from a bam to a gff file was used to determine quantitative
fold changes in H3K4me3 after MK treatment (Love´n et al., 2013). For the
integrative analysis, TSS with KDM5A ChIP-seq peaks after MK treatment
were filtered for those showing a significant reduction in H3K4me3 (>0.5
log2 fold down) following MK treatment. These genes were further refined
for those also showing a significant decrease in mRNA levels (>0.5 log2 fold
down, p < 0.01). For k-means clustering of ChIP-seq data and drawing average
ChIP-seq scores (SitePro), we used the integrative tools that can be found at
http://www.cistrome.org (Liu et al., 2011).
Immunofluorescence
Cos7 cells were seeded over glass coverslips and transfected with the indi-
cated plasmid. Cells were treated as described and fixed in 4% paraformalde-
hyde and permeabilized in 0.1% Triton X-100 in 1mMglycine. Coverslips were
incubated with FlagM2 (Sigma), washed, and incubated with alexa-488 (Invi-
trogen). Nuclei were stained with 0.5 mg/ml Hoechst (Invitrogen), after which
coverslips were mounted for imaging using an 80i Nikon epifluorescent micro-
scope (Nikon Imaging Center, Harvard Medical School).
IP/Kinase Assay
293T cells were transfected with pBabeHA-FLAG-KDM5A (Dr. William Kaelin)
or pBabeHA-FLAG-KDM5Amut5A and then lysed in IP buffer for subsequent IP
with Flag-agarose beads (Sigma). Beads were washed and resuspended in2702 Cell Reports 15, 2692–2704, June 21, 2016kinase assay buffer (0.2M TrisHCl [pH 7.5], 0.005M MgCl2), protease and
phosphatase inhibitors, and DMSO or 2 mM MK2206. Each reaction received
2.5 mCi g32P-ATP and recombinant purified AKT1 (ProQinase). Reactions were
incubated 30C for 30 min, and proteins were separated by SDS-PAGE. SDS-
PAGE gels were then fixed and kinase assays imaged using phosphorescence
(Typhoon Trio, GE).
Statistical Analysis
Western blot, biochemical fractionation, ChIP-qPCR, qPCR, and IHC assays
were performed in three independent experiments unless otherwise noted.
Mean ± SEM are reported. Statistical significance (p < 0.05) of differences
between two groups was determined by Student’s t test.
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